Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
This article was originally published in Pharmaceutical Approvals Monthly
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.
You may also be interested in...
Two more Phase III studies for the hypoactive sexual desire disorder therapy is the firm’s best financial investment, CEO Simes says, because the revised design is expected to eliminate the greater-than-expected placebo response that derailed the previous studies.
Boehringer Ingelheim shuts down development of its female desire drug due to complications in the regulatory process.